~~<i id='2DDC378D73'><strike id='2DDC378D73'><tt id='2DDC378D73'><pre id='2DDC378D73'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：comprehensive 2025-09-27 09:45:15 - browse：8451

The FDA building -- First Opinion coverage from STAT — Adobe

WASHINGTON — The Food and Drug Administration’s top cancer drug regulator doesn’t always ask for permission before taking on big initiatives.

Richard Pazdur, director of the FDA Oncology Center of Excellence, hates bureaucracy. It stifles his ideas for getting treatments to cancer patients faster — of which there are many.

To cut through that bureaucracy, Pazdur has a trick: “Don’t tell anybody,” he said to laughter at a meeting of the advocacy group Friends of Cancer Research Tuesday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： Sudafed saga points to U.S. issues with evaluating older drugs

explore

leisure time

focus

Sen.BobMenendez(D-N.J.)MichaelM.Santiago/GettyImagesWASHINGTON—WithmountingcallsforembattledSen.BobM

WSS

FDA warns medical device makers about rise in fabricated data

Kaiser Permanente unions announce official strike date

Paxlovid should be available without a positive Covid test

Medicare drug price negotiation program allowed for now

Listen: Who gets the credit for GLP

New study raises questions about niacin and heart health

focus

Wikipedia

explore

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Menendez indictment could see pharma lose a key ally

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

WHO recommends dropping component of many flu vaccines

Heart attack and stroke risk calculators need revising

Inequities make cancer less preventable for women: report

BioMarin wins approval for gene therapy to treat hemophilia A

Menendez indictment could see pharma lose a key ally

Wildfire smoke exposes gaps in outdoor worker protections

New CMS data security rules will hurt Medicare, Medicaid research

leisure time

Readout Newsletter: Bayer, Rapt Therapeutics, Sanofi shortage

New CMS data security rules will hurt Medicare, Medicaid research

Menendez indictment could see pharma lose a key ally

Researchers tackle phage therapy hurdles for wider adoption

Researchers use wearables data and AI to predict preterm birth risk

Abridge raises $150m as clinical notes automation market heats up

focus

focus

focus

focus